We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback